Latest news with #Temferon
Yahoo
08-07-2025
- Business
- Yahoo
Genenta Science Leads The Charge With 2 Other Promising Penny Stocks
As the U.S. market navigates through trade uncertainties and fluctuating indices, investors are increasingly exploring diverse investment opportunities. Penny stocks, a term often associated with smaller or newer companies, continue to offer intriguing prospects for those willing to look beyond the mainstream. By focusing on firms with robust financials and potential for growth, these stocks can present valuable opportunities without some of the typical risks associated with this segment of the market. Name Share Price Market Cap Financial Health Rating Waterdrop (WDH) $1.42 $506.33M ★★★★★★ CuriosityStream (CURI) $4.77 $278.15M ★★★★★★ WM Technology (MAPS) $0.8841 $154.72M ★★★★★★ Talkspace (TALK) $2.65 $463.46M ★★★★★★ Tuniu (TOUR) $0.9326 $95.78M ★★★★★★ Sequans Communications (SQNS) $1.43 $36.49M ★★★★★★ Cardno (COLD.F) $0.1701 $6.64M ★★★★★★ BAB (BABB) $0.84718 $6.17M ★★★★★☆ TETRA Technologies (TTI) $3.24 $452.45M ★★★★☆☆ Tandy Leather Factory (TLF) $3.15 $26.81M ★★★★★★ Click here to see the full list of 423 stocks from our US Penny Stocks screener. We'll examine a selection from our screener results. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Genenta Science S.p.A. is a clinical-stage biotechnology company in Italy focused on developing hematopoietic stem cell gene therapies for solid tumors, with a market cap of $69.50 million. Operations: Currently, there are no reported revenue segments for this clinical-stage biotechnology company. Market Cap: $69.5M Genenta Science, a clinical-stage biotechnology company, is pre-revenue with a market cap of US$69.50 million and no significant revenue streams. Despite being unprofitable, the company's short-term assets (€14.5M) cover its liabilities, and it remains debt-free with sufficient cash runway for nearly two years. Recent developments include enrolling patients in studies for glioblastoma multiforme and genitourinary tumors using Temferon, which has shown promising safety results in early trials. A collaboration with Anemocyte aims to enhance production capabilities for immuno-oncology therapies while further research on Temferon's potential continues to gain traction in scientific circles. Navigate through the intricacies of Genenta Science with our comprehensive balance sheet health report here. Evaluate Genenta Science's historical performance by accessing our past performance report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: GSI Technology, Inc. designs, develops, and markets semiconductor memory solutions for various industries including networking and aerospace, with a market cap of $98.67 million. Operations: The company's revenue is primarily derived from the design, development, and sale of integrated circuits, totaling $20.52 million. Market Cap: $98.67M GSI Technology, with a market cap of US$98.67 million, focuses on semiconductor memory solutions for sectors like networking and aerospace. Despite being unprofitable, the company has reduced losses by 4% annually over five years. Recent earnings show sales of US$5.88 million for Q4 2025, with a net loss of US$2.23 million—an improvement from the previous year's loss. The firm remains debt-free and its short-term assets cover liabilities comfortably, although it faces less than a year of cash runway if cash flow trends persist. Notably, GSI completed a significant share buyback program recently without diluting shareholders' equity further. Get an in-depth perspective on GSI Technology's performance by reading our balance sheet health report here. Examine GSI Technology's past performance report to understand how it has performed in prior years. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Dingdong (Cayman) Limited is an e-commerce company operating in China with a market cap of approximately $445.75 million. Operations: The company generates revenue primarily through its online retail operations, amounting to CN¥23.52 billion. Market Cap: $445.75M Dingdong (Cayman) Limited, with a market cap of approximately $445.75 million, has shown financial resilience in the e-commerce sector. The company reported first-quarter revenue of CN¥5.48 billion, up from CN¥5.02 billion the previous year, while net income decreased to CN¥5.62 million from CN¥10.02 million. Its strong cash position surpasses total debt and operating cash flow covers 65% of its debt obligations, indicating robust liquidity management. Dingdong's short-term assets exceed both short-term and long-term liabilities, showcasing solid balance sheet health amidst a stable earnings growth forecast of 17.71% annually despite recent profit fluctuations. Take a closer look at Dingdong (Cayman)'s potential here in our financial health report. Evaluate Dingdong (Cayman)'s prospects by accessing our earnings growth report. Reveal the 423 hidden gems among our US Penny Stocks screener with a single click here. Want To Explore Some Alternatives? Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 24 best rare earth metal stocks of the very few that mine this essential strategic resource. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include GNTA GSIT and DDL. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Associated Press
01-07-2025
- Health
- Associated Press
Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals
MILAN and NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology, today announced that a total of 38 patients were enrolled in newly diagnosed glioblastoma multiforme (TEM-GBM) study, with 25 patients receiving Temferon. Two patients have been enrolled in the TEM-LT long-term follow-up study, surviving three years from the time of 1st surgery. One of these long-term survivors has not experienced disease progression following Temferon administration and has not required any second-line therapies. The other showed initial signs of disease progression that subsequently stabilized without additional therapeutic intervention. Both these cases suggest possible Temferon-mediated control of disease progression, which warrants further investigation in larger studies. As of the April data cutoff, the survival rate at two years in the GBM trial for unmethylated MGMT (uMGMT) patients remained consistent at 29% with median overall survival holding steady at 17 months. In historical cohorts, uMGMT patients receiving standard of care have shown a two-year survival rate of approximately 14% and a median overall survival of 13 to 15 months. In parallel, the TEM-GU Phase 1 study—designed to enroll 12 patients with genitourinary tumors—has begun recruitment. In this trial, Temferon is administered at a fixed dose of 4 million genetically modified cells per kilogram of body weight—a level previously shown to be safe and well tolerated in the TEM-GBM dose-ranging study. Genenta aims to demonstrate the safety and tolerability of Temferon in patients with Metastatic Renal Cell Carcinoma by year-end. The study is designed to evaluate Temferon in combination with immune checkpoint inhibitors or tyrosine kinase inhibitors to assess the potential for immunologic synergy in this patient population. Further clinical updates will be shared once sufficient patient experience has been gained to support meaningful interpretation. Temferon's mechanism of action is based on the reprogramming of the tumor microenvironment, which promotes the activation and durability of adaptive immune responses. A scientific manuscript demonstrating Temferon's potential to enhance and prolong the durability of CAR-T activity in preclinical murine models of solid tumors has been accepted for publication in Science Translational Medicine. ' For the first time, we show that hematopoietic stem cells can be engineered to durably give rise to myeloid cells that localize to the tumor and reprogram its immune environment. In glioblastoma, this strategy induced a pro-inflammatory shift in macrophages and the emergence of tumor-reactive T cells, offering a promising new avenue for immune engagement against one of the most resistant cancers, ' said prof. Luigi Naldini, co-founder of Genenta Science. ' We are encouraged by the consistent clinical signals emerging from our glioblastoma trial, ' said Pierluigi Paracchi, CEO of Genenta Science. 'T hese findings reinforce our confidence in Temferon's differentiated mechanism and support our commitment to advancing the platform. ' About Genenta Science Genenta Science (Nasdaq: GNTA) is a clinical stage immuno-oncology company developing a proprietary hematopoietic stem cells therapy for the treatment of a variety of solid tumor cancers. Genenta's first in class product candidate is Temferon™, which is designed to allow the expression of immune-therapeutic payloads within the tumor microenvironment by bone marrow derived myeloid cells and enable a durable and targeted response. Genenta has completed the Phase 1 trial for newly diagnosed Glioblastoma Multiforme (GBM) patients with an unmethylated MGMT gene promoter, which suggests the potential reprogramming of the tumor microenvironment and inhibiting of myeloid induced tolerance, while allowing the induction of T cell responses, potentially breaking immune tolerance. Genenta has initiated a Phase 1/2a metastatic Renal Cell Carcinoma study that will also include a combination with immune checkpoint inhibitors. Genenta's treatments are designed as one-time monotherapies, but with the additional potential, when used in combination, to significantly enhance the efficacy of other approved therapeutics. Forward-Looking Statements Statements in this press release contain 'forward-looking statements,' within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'suggest,' 'target,' 'aim,' 'should,' 'will,' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Genenta's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the funding provided by the recently acquired Mandatory Convertible Bond, the completion and timing of Genenta's ongoing Phase 1/2a clinical trial for newly diagnosed GBM patients with uMGMT-GBM, its clinical trial for metastatic RCC or any related studies, as well as Genenta's ability to fund its research and development plans. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled 'Risk Factors' in Genenta's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of the date of this announcement, and Genenta undertakes no duty to update such information except as required under applicable law. This press release discusses product candidates that are under preclinical or clinical evaluation and that have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. Until finalized in a clinical study report, clinical trial data presented herein remain subject to adjustment as a result of clinical site audits and other review processes. No representation is made as to the safety or effectiveness of these product candidates or the use for which such product candidates are being studied. Temferon™ is an investigational product candidate for which the effectiveness and safety have not been established. In addition, Temferon™ is not approved for use in any jurisdiction. Genenta Science Media Tiziana Pollio, Mobile: +39 348 23 15 143 E-mail: [email protected]
